1822 related articles for article (PubMed ID: 25082815)
1. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Zhu Y; Knolhoff BL; Meyer MA; Nywening TM; West BL; Luo J; Wang-Gillam A; Goedegebuure SP; Linehan DC; DeNardo DG
Cancer Res; 2014 Sep; 74(18):5057-69. PubMed ID: 25082815
[TBL] [Abstract][Full Text] [Related]
2. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
[TBL] [Abstract][Full Text] [Related]
4. CSF1R
Candido JB; Morton JP; Bailey P; Campbell AD; Karim SA; Jamieson T; Lapienyte L; Gopinathan A; Clark W; McGhee EJ; Wang J; Escorcio-Correia M; Zollinger R; Roshani R; Drew L; Rishi L; Arkell R; Evans TRJ; Nixon C; Jodrell DI; Wilkinson RW; Biankin AV; Barry ST; Balkwill FR; Sansom OJ
Cell Rep; 2018 May; 23(5):1448-1460. PubMed ID: 29719257
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
Arnoletti JP; Reza J; Rosales A; Monreal A; Fanaian N; Whisner S; Srivastava M; Rivera-Otero J; Yu G; Phanstiel Iv O; Altomare DA; Tran Q; Litherland SA
PLoS One; 2022; 17(3):e0265725. PubMed ID: 35316296
[TBL] [Abstract][Full Text] [Related]
6. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.
Seifert L; Werba G; Tiwari S; Giao Ly NN; Alothman S; Alqunaibit D; Avanzi A; Barilla R; Daley D; Greco SH; Torres-Hernandez A; Pergamo M; Ochi A; Zambirinis CP; Pansari M; Rendon M; Tippens D; Hundeyin M; Mani VR; Hajdu C; Engle D; Miller G
Nature; 2016 Apr; 532(7598):245-9. PubMed ID: 27049944
[TBL] [Abstract][Full Text] [Related]
7. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer.
Vonderheide RH; Bear AS
Front Immunol; 2020; 11():605619. PubMed ID: 33304355
[TBL] [Abstract][Full Text] [Related]
9. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
10. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
[TBL] [Abstract][Full Text] [Related]
11. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
[TBL] [Abstract][Full Text] [Related]
12. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Beatty GL; Winograd R; Evans RA; Long KB; Luque SL; Lee JW; Clendenin C; Gladney WL; Knoblock DM; Guirnalda PD; Vonderheide RH
Gastroenterology; 2015 Jul; 149(1):201-10. PubMed ID: 25888329
[TBL] [Abstract][Full Text] [Related]
13. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
14. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
15. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
DeNardo DG; Brennan DJ; Rexhepaj E; Ruffell B; Shiao SL; Madden SF; Gallagher WM; Wadhwani N; Keil SD; Junaid SA; Rugo HS; Hwang ES; Jirström K; West BL; Coussens LM
Cancer Discov; 2011 Jun; 1(1):54-67. PubMed ID: 22039576
[TBL] [Abstract][Full Text] [Related]
16. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
[TBL] [Abstract][Full Text] [Related]
17. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.
Quaranta V; Rainer C; Nielsen SR; Raymant ML; Ahmed MS; Engle DD; Taylor A; Murray T; Campbell F; Palmer DH; Tuveson DA; Mielgo A; Schmid MC
Cancer Res; 2018 Aug; 78(15):4253-4269. PubMed ID: 29789416
[TBL] [Abstract][Full Text] [Related]
19. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
[TBL] [Abstract][Full Text] [Related]
20. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]